Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Medicine (Baltimore) ; 102(31): e34533, 2023 Aug 04.
Artigo em Inglês | MEDLINE | ID: mdl-37543826

RESUMO

RATIONALE: Although IgG4-related disease (IgG4-RD) can affect various organs, its association with a cardiac mass is exceptionally rare. Here, we report a case of a woman with IgG4-RD and a cardiac mass and discuss 10 similar cases reported previously. PATIENT CONCERNS: A 65-year-old woman was referred to our hospital for chest discomfort and back pain. DIAGNOSES: In accordance with the 2019 ACR/EULAR diagnostic criteria for IgG4-RD, she was diagnosed with IgG4-RD based on dense lymphocytic infiltration on histopathology, IgG/IgG4-positive cell ratio <40%, >10/hpf IgG4-positive cells on immunostaining, and paraspinal zone soft tissue lesions in the chest. INTERVENTIONS: An external pacemaker was implanted for the complete atrioventricular block on the electrocardiogram. After the diagnosis of IgG4-RD, she was treated with glucocorticoids and rituximab. OUTCOMES: She remains under observation without disease recurrence. LESSONS: IgG4-RD are usually treated with glucocorticoids; however, in cases of a cardiac mass, life-threatening complications may occur and surgery is often needed. Combination therapy with glucocorticoids and rituximab may be effective even in patients with IgG4-RD and cardiac mass, which may avoid the need of invasive treatments, such as surgery.


Assuntos
Glucocorticoides , Doença Relacionada a Imunoglobulina G4 , Feminino , Humanos , Idoso , Glucocorticoides/uso terapêutico , Doença Relacionada a Imunoglobulina G4/complicações , Doença Relacionada a Imunoglobulina G4/diagnóstico , Doença Relacionada a Imunoglobulina G4/terapia , Rituximab/uso terapêutico , Imunoglobulina G , Diagnóstico Diferencial
2.
J Nat Med ; 63(3): 355-9, 2009 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-19387769

RESUMO

The screening of Piperaceous plants for xanthine oxidase inhibitory activity revealed that the extract of the leaves of Piper betle possesses potent activity. Activity-guided purification led us to obtain hydroxychavicol as an active principle. Hydroxychavicol is a more potent xanthine oxidase inhibitor than allopurinol, which is clinically used for the treatment of hyperuricemia.


Assuntos
Inibidores Enzimáticos/farmacologia , Eugenol/análogos & derivados , Piper betle/química , Extratos Vegetais/química , Folhas de Planta/química , Xantina Oxidase/antagonistas & inibidores , Inibidores Enzimáticos/química , Eugenol/química , Eugenol/farmacologia , Estrutura Molecular
3.
Bioorg Med Chem ; 16(11): 6131-44, 2008 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-18468909

RESUMO

Vancomycin is mainly used as an antibacterial agent of last resort, but recently vancomycin-resistant bacterial strains have been emerging. Although new antimicrobials have been developed in order to overcome drug-resistant bacteria, many are structurally complex beta-lactams or quinolones. In this study, we aimed to create new anti-drug-resistance antibacterials which can be synthesized in a few steps from inexpensive starting materials. Since sulfa drugs function as p-aminobenzoic acid mimics and inhibit dihydropteroate synthase (DHPS) in the folate pathway, we hypothesized that sulfa derivatives would act as folate metabolite-mimics and inhibit bacterial folate metabolism. Screening of our sulfonanilide libraries, including benzenesulfonanilide-type cyclooxygenase-1-selective inhibitors, led us to discover benzenesulfonanilides with potent anti-methicillin-resistant Staphylococcus aureus (MRSA)/vancomycin-resistant Enterococcus (VRE) activity, that is, N-3,5-bis(trifluoromethyl)phenyl-3,5-dichlorobenzenesulfonanilide (16b) [MIC=0.5microg/mL (MRSA), 1.0microg/mL (VRE)], and 3,5-bis(trifluoromethyl)-N-(3,5-dichlorophenyl)benzenesulfonanilide (16c) [MIC=0.5microg/mL (MRSA), 1.0microg/mL (VRE)]. These compounds are more active than vancomycin [MIC=2.0microg/mL (MRSA), 125microg/mL (VRE)], but do not possess an amino group, which is essential for DHPS inhibition by sulfa drugs. These results suggested that the mechanism of antibacterial action of compounds 16b and 16c is different from that of sulfa drugs. We also confirmed the activity of these compounds against clinical isolates of Gram-positive bacteria.


Assuntos
Anilidas/síntese química , Antibacterianos/síntese química , Enterococcus faecium/efeitos dos fármacos , Resistência a Meticilina , Staphylococcus aureus/efeitos dos fármacos , Sulfonamidas/síntese química , Resistência a Vancomicina , Anilidas/farmacologia , Anilidas/toxicidade , Animais , Antibacterianos/farmacologia , Antibacterianos/toxicidade , Ciclo-Oxigenase 1/metabolismo , Inibidores de Ciclo-Oxigenase/síntese química , Inibidores de Ciclo-Oxigenase/farmacologia , Inibidores de Ciclo-Oxigenase/toxicidade , Desenho de Fármacos , Enterococcus faecium/isolamento & purificação , Humanos , Masculino , Proteínas de Membrana/metabolismo , Camundongos , Testes de Sensibilidade Microbiana , Staphylococcus aureus/isolamento & purificação , Sulfonamidas/farmacologia , Sulfonamidas/toxicidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...